Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.42 |
| ▸ | APLNR | P35414 | 7/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.33 |
| ▸ | TUBB | P07437 | 2/20 | 0.33 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.33 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.33 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.33 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.33 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.33 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.33 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.33 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.33 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.33 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.33 |
| ▸ | TUBB6 | Q9BUF5 | 2/20 | 0.33 |
| ▸ | TUBB2B | Q9BVA1 | 2/20 | 0.33 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14279346 | 0.83 | SIRT6 (0.40) | SIRT6APLNRLMNASMN1; SMN2TSHR | |
| SCHEMBL17544060 | 0.80 | CA12 (0.33) | — | |
| SCHEMBL15686910 | 0.79 | POLB (0.36) | LMNATSHRNAAA | |
| SCHEMBL21906535 | 0.79 | RXRB (0.40) | SMN1; SMN2 | |
| SCHEMBL21906359 | 0.77 | KDM4E (0.47) | LMNASMN1; SMN2 | |
| SCHEMBL9952658 | 0.77 | SIRT6 (0.35) | SIRT6LMNASMN1; SMN2TSHR | |
| SCHEMBL20349150 | 0.77 | KDM4E (0.30) | LMNATSHR | |
| SCHEMBL21906701 | 0.76 | RXRB (0.42) | — | |
| SCHEMBL21906497 | 0.76 | L3MBTL1 (0.46) | — | |
| SCHEMBL21906704 | 0.75 | RXRB (0.43) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12258355-B2 | Probes for imaging huntingtin protein | CHDI FOUNDATION, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| US-12036291-B2 | Probes for imaging huntingtin protein | CHDI FOUNDATION, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12036291-B2 | Probes for imaging huntingtin protein | CHDI FOUNDATION, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12036291-B2 | Probes for imaging huntingtin protein | CHDI FOUNDATION, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-11851446-B2 | Probes for imaging Huntingtin protein | CHDI FOUNDATION, INC. (US) | 2023-12-26 | — | — | US | disclosed |
| US-20230212190-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230212190-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230212190-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION, INC. | 2023-07-06 | — | — | US | disclosed |
| EP-3867244-B1 | 4-PYRAZIN-2-YLMETHYL-MORPHOLINE DERIVATIVES AND THE USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM INT (DE) | 2023-01-18 | — | — | EP | disclosed |
| EP-4006016-A2 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI Foundation, Inc. (US) | 2022-06-01 | — | — | EP | disclosed |
| US-20170281804-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | EVOTEC (UK) LTD. (GB) | 2017-10-05 | — | — | US | disclosed |
| US-20170283439-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CCHDI Foundation Inc. (US) | 2017-10-05 | — | — | US | disclosed |
| EP-3197277-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI Foundation, Inc. (US) | 2017-08-02 | — | — | EP | disclosed |
| EP-3186233-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI Foundation, Inc. (US) | 2017-07-05 | — | — | EP | disclosed |
| EP-3186241-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI Foundation, Inc. (US) | 2017-07-05 | — | — | EP | disclosed |
| WO-2016033445-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION, INC. (US) | 2016-03-03 | — | — | WO | disclosed |
| WO-2016033445-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION, INC. (US) | 2016-03-03 | — | — | WO | disclosed |
| WO-2016033436-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION, INC. (US) | 2016-03-03 | — | — | WO | disclosed |
| WO-2016033440-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION, INC. (US) | 2016-03-03 | — | — | WO | disclosed |
| WO-2016033440-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION, INC. (US) | 2016-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11851446-B2 | Probes for imaging Huntingtin protein | HTT, HYPK, HSPBP1 | SIRT6 2190/4885APLNR 1081/4885LMNA 2021/4885 |
| US-20230212190-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | HTT, HYPK, HSPBP1 | SIRT6 2190/4885APLNR 1081/4885LMNA 2021/4885 |
| US-20170281804-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | HTT, HYPK, HSPBP1 | SIRT6 2190/4885APLNR 1081/4885LMNA 2021/4885 |
| US-20170283439-A1 | PROBES FOR IMAGING HUNTINGTIN PROTEIN | HTT, HYPK, HSPBP1 | SIRT6 2190/4885APLNR 1081/4885LMNA 2021/4885 |
| US-12036291-B2 | Probes for imaging huntingtin protein | HTT, HYPK, HSPBP1 | SIRT6 2190/4885APLNR 1081/4885LMNA 2021/4885 |
| US-12258355-B2 | Probes for imaging huntingtin protein | HTT, HYPK, HSPBP1 | SIRT6 2190/4885APLNR 1081/4885LMNA 2021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.